image credit: Adobe Stock

Convergent raises $90M to develop its radiopharmaceutical for prostate cancer

May 5, 2023

While radiopharmaceuticals can be difficult to manufacture, they are an attractive way to more selectively direct radiation to tumor cells while sparing healthy tissue.

Prostate cancer in particular has been a target of choice for radiopharmaceutical developers looking to add new drugs to surgery, chemotherapy and hormonal treatment options. Novartis, for instance, sells a radiopharmaceutical called Pluvicto for advanced forms of prostate cancer. (It also sells another radiopharmaceutical, Lutathera, for tumors of the pancreas or gastrointestinal tract.)

Read More on Biopharma Dive